Patents by Inventor June Gladman
June Gladman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11919975Abstract: The present invention relates to a process for producing a low endotoxin alkali chitosan, chitin, chitosan derivative or chitin derivative, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan, chitin, chitosan derivative or chitin derivative with an alkali solution to form a mixture; leaving the mixture for a period of less than 1 hour and optionally drying the mixture. The low endotoxin alkali chitosan may be used in the manufacture of other useful chitosan based products.Type: GrantFiled: May 29, 2014Date of Patent: March 5, 2024Assignee: MEDTRADE PRODUCTS LIMITEDInventors: Craig Hardy, Andrew Hoggarth, June Gladman
-
Patent number: 11534525Abstract: The present invention relates to a process for producing a low endotoxin alkali chitosan, chitin, chitosan derivative or chitin derivative, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan, chitin, chitosan derivative or chitin derivative with an alkali solution having a concentration of less than 0.25M to form a mixture; leaving the mixture for a period of less than 12 hours and optionally drying the mixture. The low endotoxin alkali chitosan may be used in the manufacture of other useful chitosan based products.Type: GrantFiled: May 29, 2014Date of Patent: December 27, 2022Assignee: MEDTRADE PRODUCTS LIMITEDInventors: Craig Hardy, Andrew Hoggarth, June Gladman
-
Patent number: 11498981Abstract: The present invention relates to a process for producing a low endotoxin alkali chitosan, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan with an alkali solution to form a mixture and leaving the mixture for at least about 12 hours. The low endotoxin alkali chitosan may be used the manufacture of other useful chitosan based products.Type: GrantFiled: February 24, 2016Date of Patent: November 15, 2022Assignee: MEDTRADE PRODUCTS LIMITEDInventors: June Gladman, Craig Hardy, Andrew Hoggarth
-
Patent number: 11485798Abstract: The present invention relates to a process for producing a low endotoxin alkali chitosan, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan with an alkali solution to form a mixture and leaving the mixture for at least about 12 hours. The low endotoxin alkali chitosan may be used in the manufacture of other useful chitosan based products.Type: GrantFiled: March 25, 2013Date of Patent: November 1, 2022Assignee: MEDTRADE PRODUCTS LIMITEDInventors: June Gladman, Craig Hardy, Andrew Hoggarth
-
Patent number: 10933160Abstract: In one aspect, the present invention includes a haemostat composition that has been washed with an alkali solution to reduce the presence of endotoxins, and which is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.Type: GrantFiled: May 28, 2014Date of Patent: March 2, 2021Assignee: MEDTRADE PRODUCTS LIMITEDInventors: Craig Hardy, Andrew Hoggarth, June Gladman
-
Patent number: 10434212Abstract: The present invention relates to a fibrous hemostat composition that is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilized by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.Type: GrantFiled: April 4, 2017Date of Patent: October 8, 2019Assignee: MEDTRADE PRODUCTS LIMITEDInventors: Craig Hardy, Andrew Hoggarth, June Gladman
-
Patent number: 10300166Abstract: The present invention relates to a fibrous haemostat composition that is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.Type: GrantFiled: April 4, 2017Date of Patent: May 28, 2019Assignee: MEDTRADE PRODUCTS LIMITEDInventors: Craig Hardy, Andrew Hoggarth, June Gladman
-
Patent number: 9867900Abstract: The present invention relates to a fibrous haemostat composition that is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilized by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.Type: GrantFiled: May 28, 2014Date of Patent: January 16, 2018Assignee: Medtrade Products LimitedInventors: Craig Hardy, Andrew Hoggarth, June Gladman
-
Publication number: 20170258959Abstract: In one aspect, the present invention includes a haemostat composition that includes a chitosan, chitosan salt or chitosan derivative, and a physiologically acceptable acid selected from the group consisting of lactic acid, formic acid, acetic acid, ascorbic acid, halogen acetic acids, propanoic acid, propenoic acid, acrylic acid, glyoxylic acid, pyruvic acid or a hydroxy propionic/butanoic acid, and combinations of any two or more thereof; or one or more acids selected from hydrochloric acid and sulphuric acid. The haemostat composition is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.Type: ApplicationFiled: May 22, 2017Publication date: September 14, 2017Inventors: Craig Hardy, Andrew Hoggarth, June Gladman
-
Publication number: 20170258958Abstract: In one aspect, the present invention includes a haemostat composition that includes a chitosan, chitosan salt or chitosan derivative, and a physiologically acceptable acid, which is present in the amount of 45-70% by weight of the haemostat composition. The haemostat composition is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.Type: ApplicationFiled: May 22, 2017Publication date: September 14, 2017Inventors: Craig Hardy, Andrew Hoggarth, June Gladman
-
Publication number: 20170202997Abstract: The present invention relates to a fibrous haemostat composition that is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.Type: ApplicationFiled: April 4, 2017Publication date: July 20, 2017Inventors: Craig Hardy, Andrew Hoggarth, June Gladman
-
Publication number: 20170202994Abstract: The present invention relates to a fibrous haemostat composition that is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.Type: ApplicationFiled: April 4, 2017Publication date: July 20, 2017Inventors: Craig Hardy, Andrew Hoggarth, June Gladman
-
Publication number: 20160168277Abstract: The present invention relates to a process for producing a low endotoxin alkali chitosan, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan with an alkali solution to form a mixture and leaving the mixture for at least about 12 hours. The low endotoxin alkali chitosan may be used the manufacture of other useful chitosan based products.Type: ApplicationFiled: February 24, 2016Publication date: June 16, 2016Inventors: June Gladman, Craig Hardy, Andrew Hoggarth
-
Publication number: 20160121020Abstract: The present invention relates to a fibrous haemostat composition that is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.Type: ApplicationFiled: May 28, 2014Publication date: May 5, 2016Inventors: Craig Hardy, Andrew Hoggarth, June Gladman
-
Publication number: 20160121022Abstract: The present invention relates to a process for producing a low endotoxin alkali chitosan, chitin, chitosan derivative or chitin derivative, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan, chitin, chitosan derivative or chitin derivative with an alkali solution having a concentration of less than 0.25 M to form a mixture; leaving the mixture for a period of less than 12 hours and optionally drying the mixture. The low endotoxin alkali chitosan may be used in the manufacture of other useful chitosan based products.Type: ApplicationFiled: May 29, 2014Publication date: May 5, 2016Inventors: Craig Hardy, Andrew Hoggarth, June Gladman
-
Publication number: 20160106882Abstract: The present invention relates to a haemostat composition that is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.Type: ApplicationFiled: May 28, 2014Publication date: April 21, 2016Inventors: Craig Hardy, Andrew Hoggarth, June Gladman
-
Publication number: 20150080335Abstract: The present invention relates to a process for producing a low endotoxin alkali chitosan, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting chitosan with an alkali solution to form a mixture and leaving the mixture for at least about 12 hours. The low endotoxin alkali chitosan may be used in the manufacture of other useful chitosan based products.Type: ApplicationFiled: March 25, 2013Publication date: March 19, 2015Inventors: June Gladman, Craig Hardy, Andrew Hoggarth
-
Publication number: 20070042024Abstract: A material for use as a wound dressing, the material being in the form of a roll and comprising gel forming fibers and the material having lines of longitudinal stitching.Type: ApplicationFiled: June 30, 2006Publication date: February 22, 2007Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: June Gladman, Bryan Griffiths
-
Publication number: 20070042025Abstract: A body shaped wound dressing wherein the dressing is a knitted or woven garment comprising a cellulosic yarn, which garment has been carboxymethylated at least in parts of its wound contacting surface.Type: ApplicationFiled: June 30, 2006Publication date: February 22, 2007Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: June Gladman, Bryan Griffiths